Sanofi and Sobi Report P-III Study (XTEND-Kids) Results of Altuviiio for the Treatment of Hemophilia A in Children Aged <12 Years
- The P-III study (XTEND-Kids) evaluated the safety, efficacy, and PK of Altuviiio (50IU/kg, qw for 52wk.) in prior treated 75 patients aged <12yrs. with sev. hemophilia A. The 1EPs of the study were the occurrence of inhibitor development
- The trial met its 1EPs with no factor VIII inhibitors detected & confirming the safety profile of efanesoctocog alfa in prior treated patients under 12yrs. of age
- Altuviiio is a high-sustained FVIII therapy & has been approved in the US for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in adults and children in Feb 2023; BTD from the US FDA in May 2022; FTD in Feb 2021 and ODD in 2017 while ODD from the EC in June 2019
Ref: Globenewswire | Image: Sanofi
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.